Skip to Main Content

Oncology

Andre Goy  Andre Goy, M.D., M.S.​

  Chair of Oncology

  Email

Department of Oncology Faculty Publications (By Year)

  • Advani, R. H., Moskowitz, A. J., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., . . . Herrera, A. F. (2021). Brentuximab vedotin in combination with nivolumab in relapsed or refractory hodgkin lymphoma: 3-year study results. Blood, 138(6), 427-438. doi:10.1182/blood.2020009178
  • Berry, D. A., Ip, A., Lewis, B. E., Berry, S. M., Berry, N. S., MrKulic, M., . . . Goldberg, S. L. (2021). Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19. PLoS ONE, 16(7 July) doi:10.1371/journal.pone.0255228
  • Leslie, L. A. (2021). Novel therapies for follicular lymphoma and other indolent non-hodgkin lymphomas. Current Treatment Options in Oncology, 22(12) doi:10.1007/s11864-021-00909-1
  • Zayac, A. S., Evens, A. M., Danilov, A., Smith, S. D., Jagadeesh, D., Leslie, L. A., . . . Olszewski, A. J. (2021). Outcomes of burkitt lymphoma with central nervous system involvement: Evidence from a large multicenter cohort study. Haematologica, 106(7), 1932-1942. doi:10.3324/haematol.2020.270876
  • Feldman, T., Zou, D., Rebeira, M., Lee, J., Fanale, M., Manley, T., . . . Kansal, A. (2020). Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL. American Journal of Managed Care, 26(2), E41-E49.
  • Leslie, L. A. (2020). Clinical use of emerging therapies in relapsed or refractory follicular lymphoma. Clinical Advances in Hematology & Oncology : H&O, 18(12), 15-19.
  • Mato, A. R., Roeker, L. E., Lamanna, N., Allan, J. N., Leslie, L., Pagel, J. M., . . . Eyre, T. A. (2020). Outcomes of COVID-19 in patients with CLL: A multicenter international experience. Blood, 136(10), 1134-1143. doi:10.1182/blood.2020006965
  • Pagel, J. M., Burke, J. M., & Leslie, L. A. (2020). Refining the management of relapsed or refractory follicular lymphoma. Clinical Advances in Hematology & Oncology : H&O, 18(12), 1-24.
  • Pagel, J. M., Burke, J. M., & Leslie, L. A. (2020). Refining the management of relapsed or refractory follicular lymphoma: Case scenarios. Clinical Advances in Hematology & Oncology : H&O, 18(12), 20-21.
  • Roeker, L. E., Knorr, D. A., Pessin, M. S., Ramanathan, L. V., Thompson, M. C., Leslie, L. A., . . . Mato, A. R. (2020). Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia, 34(11), 3047-3049. doi:10.1038/s41375-020-01030-2
  • Bair, S. M., Strelec, L. E., Feldman, T. A., Ahmed, G., Armand, P., Shah, N. N., . . . Svoboda, J. (2019). Outcomes and toxicities of programmed death-1 (PD-1) inhibitors in hodgkin lymphoma patients in the united states: A real-world, multicenter retrospective analysis. Oncologist, 24(7), 955-962. doi:10.1634/theoncologist.2018-0538
  • Chihara, D., Wong, S., Feldman, T., Fanale, M. A., Sanchez, L., Connors, J. M., . . . Oki, Y. (2019). Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin. Hematological Oncology, 37(1), 35-38. doi:10.1002/hon.2560
  • Leslie, L. A., Feldman, T. A., McNeill, A., Timberg, M., Iida, H., & Goy, A. H. (2019). Contemporary management of nodal and primary splenic marginal zone lymphoma. Expert Review of Hematology, 12(12), 1011-1022. doi:10.1080/17474086.2020.1681962
  • Nowakowski, G. S., Feldman, T., Rimsza, L. M., Westin, J. R., Witzig, T. E., & Zinzani, P. L. (2019). Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. Blood Cancer Journal, 9(6) doi:10.1038/s41408-019-0208-6
  • Herrera, A. F., Moskowitz, A. J., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., . . . Advani, R. H. (2018). Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory hodgkin lymphoma. Blood, 131(11), 1183-1194. doi:10.1182/blood-2017-10-811224